within Pharmacolibrary.Drugs.ATC.L;

model L04AA48
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.46,
    Cl             = 0.00016383333333333335,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.151,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0105,
    Tlag           = 15.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AA48</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Belumosudil is an orally administered, selective inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). It is approved for the treatment of chronic graft-versus-host disease (cGVHD) in adults and pediatric patients aged 12 years and older who have received at least two prior lines of systemic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult healthy volunteers and patients with cGVHD, based primarily on product labeling and limited clinical trial reports.</p><h4>References</h4><ol><li><p>Wang, Y, et al., &amp; Zhang, Y (2024). A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China. <i>BMC medicine</i> 22(1) 142–None. DOI:<a href=&quot;https://doi.org/10.1186/s12916-024-03348-5&quot;>10.1186/s12916-024-03348-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38532458/&quot;>https://pubmed.ncbi.nlm.nih.gov/38532458</a></p></li><li><p>Schueller, O, et al., &amp; Patel, J (2024). Two-Part Phase 1 Study to Evaluate the Taste Profile of Novel Belumosudil Oral Suspensions and Assess the Relative Bioavailability and Food Effect of the Selected Belumosudil Oral Suspension Compared With Oral Tablet Reference in Healthy Male Participants. <i>Clinical pharmacology in drug development</i> 13(5) 491–498. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1378&quot;>10.1002/cpdd.1378</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38345529/&quot;>https://pubmed.ncbi.nlm.nih.gov/38345529</a></p></li><li><p>Schueller, O, et al., &amp; Patel, J (2022). A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors. <i>Clinical pharmacology in drug development</i> 11(7) 795–806. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1082&quot;>10.1002/cpdd.1082</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35230741/&quot;>https://pubmed.ncbi.nlm.nih.gov/35230741</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AA48;
